Omeros Corp (OMER): Total Assets
$325.63M
As of 2025-12-31
$286.83M
As of 2026-06-30
-18.0%
3-year compound annual growth
+12.5%
5-year compound annual growth
+20.9%
10-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $325.63M | +17.5% | 2026-03-31, Balance as of period end |
| 2024-12-31 | $277.08M | -26.8% | 2026-03-31, Balance as of period end |
| 2023-12-31 | $378.27M | -36.0% | 2025-03-31, Balance as of period end |
| 2022-12-31 | $590.97M | +41.0% | 2024-04-01, Balance as of period end |
| 2021-12-31 | $419.27M | +131.6% | 2023-03-13, Balance as of period end |
| 2020-12-31 | $181.04M | +32.2% | 2022-03-01, Balance as of period end |
| 2019-12-31 | $136.97M | +42.8% | 2021-03-01, Balance as of period end |
| 2018-12-31 | $95.94M | -17.5% | 2020-03-02, Balance as of period end |
| 2017-12-31 | $116.33M | +72.9% | 2019-03-01, Balance as of period end |
| 2016-12-31 | $67.28M | +37.3% | 2018-03-01, Balance as of period end |
| 2015-12-31 | $48.99M | +352.2% | 2017-03-16, Balance as of period end |
| 2014-12-31 | $10.83M | n/c | 2016-03-15, Balance as of period end |
| 2013-12-31 | $16.54M | -37.8% | 2015-03-16, Balance as of period end |
| 2012-12-31 | $26.57M | -1.5% | 2014-03-13, Balance as of period end |
| 2011-12-31 | $26.98M | -41.0% | 2013-03-18, Balance as of period end |
| 2010-12-31 | $45.70M | n/a | 2012-03-15, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| Omeros Corp (OMER) | 2025-12-31 | $325.63M | +17.5% |
| Sionna Therapeutics, Inc. (SION) | 2025-12-31 | $325.95M | +75.5% |
| Prothena Corp Public Ltd Co (PRTA) | 2025-12-31 | $326.80M | -40.3% |
| ARS Pharmaceuticals, Inc. (SPRY) | 2025-12-31 | $327.65M | -6.7% |
| Liquidia Corp (LQDA) | 2025-12-31 | $327.93M | +42.4% |
| ADC Therapeutics SA (ADCT) | 2025-12-31 | $323.15M | +0.4% |
| Rocket Pharmaceuticals, Inc. (RCKT) | 2025-12-31 | $330.45M | -37.4% |
| Amylyx Pharmaceuticals, Inc. (AMLX) | 2025-12-31 | $332.64M | +71.8% |
| ArriVent BioPharma, Inc. (AVBP) | 2025-12-31 | $333.17M | +21.2% |
Compare OMER, SION, PRTA, SPRY side by side · Screen every company in Pharmaceutical Preparations ↗